Know Cancer

or
forgot password

Platelet Modulation in the Control of Angiogenesis: The Impact of Tamoxifen and Aromatase Inhibitors on Platelet Activation and Angiogenic Proteins


N/A
18 Years
N/A
Open (Enrolling)
Female
Breast Cancer

Thank you

Trial Information

Platelet Modulation in the Control of Angiogenesis: The Impact of Tamoxifen and Aromatase Inhibitors on Platelet Activation and Angiogenic Proteins


Inclusion Criteria:



- women routinely taking tamoxifen or aromatase inhibitor therapy as prescribed by
their oncologist

Exclusion Criteria:

- Use of heparin, warfarin

Type of Study:

Observational

Study Design:

N/A

Outcome Measure:

Angiogenic Protein levels

Outcome Time Frame:

following 6 months of therapy

Safety Issue:

No

Principal Investigator

Chris E Holmes, MD, PhD

Investigator Role:

Principal Investigator

Investigator Affiliation:

University of Vermont

Authority:

United States: Institutional Review Board

Study ID:

V0805

NCT ID:

NCT01341171

Start Date:

August 2009

Completion Date:

September 2012

Related Keywords:

  • Breast Cancer
  • tamoxifen
  • aromatase inhibitors
  • breast cancer
  • platelets
  • Breast Neoplasms

Name

Location

University Of VermontBurlington,, Vermont  05403